12
ALL12
Virios TherapeuticsYear
12
ALL3
20236
20222
20211
2020DEALS // DEV.
12
ALL3
Deals9
DevelopmentsCountry
12
ALL12
U.S.A12
ALL8
Not Applicable3
ThinkEquity1
University of AlabamaTherapeutic Area
12
ALL12
MusculoskeletalStudy Phase
12
ALL12
Phase IIDeal Type
3
ALL3
Public OfferingProduct Type
12
ALL12
Small moleculeDosage Form
11
ALL6
Pill5
TabletLead Product
12
ALL12
FamciclovirTarget
8
ALL3
HSV-1 DNA polymerase5
HSV-1 DNA replicationLead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : IMC-1 (famciclovir) is a fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. It is being investegated for the treatment of fib...
Brand Name : IMC-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 09, 2023
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : IMC-1 (famciclovir) is a fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. It is being investegated for the treatment of fib...
Brand Name : IMC-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 24, 2023
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : IMC-1 (Famciclovir) is a fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. IMC-1 has been granted fast track designation by ...
Brand Name : IMC-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 05, 2023
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : ThinkEquity
Deal Size : Undisclosed
Deal Type : Public Offering
Virios Therapeutics, Inc. Announces Closing of Public Offering
Details : The Company intends to use the net proceeds from the offering primarily to further advance the clinical development of IMC-1 (famciclovir) and for working capital and general corporate purposes.
Brand Name : IMC-1
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 22, 2022
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : ThinkEquity
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : ThinkEquity
Deal Size : $10.0 million
Deal Type : Public Offering
Virios Therapeutics, Inc. Announces Pricing of Public Offering
Details : The Company intends to use the net proceeds from the offering primarily to further advance the clinical development of IMC-1 (famciclovir) and for working capital and general corporate purposes.
Brand Name : IMC-1
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 19, 2022
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : ThinkEquity
Deal Size : $10.0 million
Deal Type : Public Offering
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia
Details : IMC-1 (famciclovir) was well-tolerated overall, with only 4.6% of patients dropping out due to adverse events, as compared with 8.1% of placebo treated patients. No adverse event category in the IMC-1 group exceeded a 4% rate with the exception of COVID-...
Brand Name : IMC-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 19, 2022
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Study Phase : Preclinical
Sponsor : University of Alabama
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Analysis of gastric mucosa biopsies revealed a significant positive association between actively replicating gastric HSV-1 and multiple functional gastrointestinal disorders, with and without concomitant FM.
Brand Name : IMC-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2022
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Sponsor : University of Alabama
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. This dual mechanism antiviral therapy is designed to synergistically suppress herpes virus activation and replication.
Brand Name : IMC-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 28, 2022
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Virios Therapeutics to Present at the 34th Annual Roth Conference on Monday, March 14, 2022
Details : IMC-1, a fixed-dose combination of famciclovir and celecoxib, designed to synergistically suppress herpes virus replication, with end goal of reducing virally promoted disease symptom is currently being tested in FORTRESS trial designed to set stage for ...
Brand Name : IMC-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 08, 2022
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Virios Therapeutics Granted New Patent for Antiviral Inhibitor Combination
Details : This portfolio of patents also covers the Company’s lead development candidate IMC-1, a synergistic, fixed dose combination of famciclovir and celecoxib, which is in Phase 2b development for the treatment of fibromyalgia.
Brand Name : IMC-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 08, 2021
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?